Valuation : Simulations Plus, Inc.

Market Cap 373M 321M 304M 275M 517M 35.59B 519M 3.61B 1.39B 18.11B 1.4B 1.37B 57.22B P/E 2026 *
43.9x
P/E 2027 * 40.3x
Enterprise Value 373M 321M 304M 275M 517M 35.59B 519M 3.61B 1.39B 18.11B 1.4B 1.37B 57.22B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 4.32x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
1 week-0.05%
Current month+0.11%
1 month+0.55%
3 months+12.87%
6 months+49.39%
Current year+1.04%
1 week 18.42
Extreme 18.42
18.44
1 month 18.33
Extreme 18.33
18.46
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.1
Extreme 8.1011
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Sell

Executive/Senior Manager

-1,000 0.0050%
06/07/26 Sell

Executive/Senior Manager

-1,000 0.0050%
01/07/26 Sell

Founder

-4,177 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.05%+22.39%-55.02% 373M
+0.54%-4.61%-5.08%+21.63% 42.48B
-1.51%-5.52%-44.93%+127.19% 12.31B
-0.28%-1.52%-10.90%+75.78% 5.69B
+9.65%+1.98%+49.43% - 4.34B
+2.14%-4.09% - - 2.02B
+1.67%-4.60%+3.02%-38.62% 1.5B
+0.89%-4.85%-36.83% - 1.04B
0.00%-0.58%+14.80%+152.22% 1.01B
-2.09%-5.21%+34.13%+37.70% 884M
Average +1.10%-2.72%+2.89%+45.84% 7.16B
Weighted average by Cap. +0.70%-4.02%-8.57%+47.09%

Financials

2026 *2027 *
Net sales 81.87M 70.54M 66.79M 60.54M 114M 7.82B 114M 793M 305M 3.98B 307M 301M 12.57B 86.26M 74.32M 70.37M 63.78M 120M 8.24B 120M 836M 321M 4.19B 324M 317M 13.25B
Net income 9.53M 8.21M 7.78M 7.05M 13.23M 911M 13.29M 92.38M 35.52M 463M 35.8M 35.02M 1.46B 10.18M 8.77M 8.31M 7.53M 14.12M 973M 14.2M 98.65M 37.94M 495M 38.24M 37.4M 1.56B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
11/09/26 $18.42 0.00% 133,568
10/09/26 $18.42 0.00% 187,876
09/09/26 $18.42 0.00% 181,150
08/09/26 $18.42 -0.05% 156,748
04/09/26 $18.43 +0.05% 79,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.42USD
Average target price
17.25USD
Spread / Average Target
-6.35%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!